Calton & Associates, Inc. Sellas Life Sciences Group, Inc. Transaction History
Calton & Associates, Inc.
- $250 Million
- Q3 2024
A detailed history of Calton & Associates, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Calton & Associates, Inc. holds 14,000 shares of SLS stock, worth $13,720. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,000
Previous 5,916
136.65%
Holding current value
$13,720
Previous $7,000
142.86%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.25 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$777,9580.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$593,0870.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$421,7600.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$302,2963.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $20.1M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...